

# Grover P Miller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4666672/publications.pdf>

Version: 2024-02-01

72  
papers

1,989  
citations

279798

23  
h-index

265206

42  
g-index

75  
all docs

75  
docs citations

75  
times ranked

1954  
citing authors

#	ARTICLE	IF	CITATIONS
1	Elucidation of Distinct Ligand Binding Sites for Cytochrome P450 3A4. <i>Biochemistry</i> , 2000, 39, 5929-5939.	2.5	232
2	Rate-Determining Steps in Phenacetin Oxidations by Human Cytochrome P450 1A2 and Selected Mutants. <i>Biochemistry</i> , 2000, 39, 11319-11329.	2.5	135
3	Modeling Epoxidation of Drug-like Molecules with a Deep Machine Learning Network. <i>ACS Central Science</i> , 2015, 1, 168-180.	11.3	130
4	Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1496-1504.	3.3	129
5	Modeling Reactivity to Biological Macromolecules with a Deep Multitask Network. <i>ACS Central Science</i> , 2016, 2, 529-537.	11.3	76
6	Site of Reactivity Models Predict Molecular Reactivity of Diverse Chemicals with Glutathione. <i>Chemical Research in Toxicology</i> , 2015, 28, 797-809.	3.3	70
7	Diversity in the Oxidation of Substrates by Cytochrome P450 2D6: A Lack of an Obligatory Role of Aspartate 301 in Substrate Electrostatic Bonding. <i>Biochemistry</i> , 2002, 41, 11025-11034.	2.5	69
8	Binding and Oxidation of Alkyl 4-Nitrophenyl Ethers by Rabbit Cytochrome P450 1A2: Evidence for Two Binding Sites. <i>Biochemistry</i> , 2001, 40, 7262-7272.	2.5	64
9	CYP2E1 Substrate Inhibition. <i>Journal of Biological Chemistry</i> , 2008, 283, 3487-3496.	3.4	64
10	Oxidation of Methoxyphenethylamines by Cytochrome P450 2D6. <i>Journal of Biological Chemistry</i> , 2002, 277, 33711-33719.	3.4	54
11	Oxidations of p-Alkoxyacylanilides Catalyzed by Human Cytochrome P450 1A2: Structure-Activity Relationships and Simulation of Rate Constants of Individual Steps in Catalysis. <i>Biochemistry</i> , 2001, 40, 4521-4530.	2.5	41
12	Assessing Cytochrome P450 and UDP-Glucuronosyltransferase Contributions to Warfarin Metabolism in Humans. <i>Chemical Research in Toxicology</i> , 2009, 22, 1239-1245.	3.3	41
13	Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 1056-1062.	2.3	41
14	Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 139-148.	2.5	39
15	Oxidation of Phenethylamine Derivatives by Cytochrome P450 2D6: The Issue of Substrate Protonation in Binding and Catalysis. <i>Biochemistry</i> , 2001, 40, 14215-14223.	2.5	37
16	Metabolism of R- and S-Warfarin by CYP2C19 into Four Hydroxywarfarins. <i>Drug Metabolism Letters</i> , 2013, 6, 157-164.	0.8	36
17	Hydroxywarfarin Metabolites Potently Inhibit CYP2C9 Metabolism of S-Warfarin. <i>Chemical Research in Toxicology</i> , 2010, 23, 939-945.	3.3	35
18	Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort. <i>PLoS Computational Biology</i> , 2021, 17, e1009053.	3.2	33

#	ARTICLE	IF	CITATIONS
19	Computational Approach to Structural Alerts: Furans, Phenols, Nitroaromatics, and Thiophenes. <i>Chemical Research in Toxicology</i> , 2017, 30, 1046-1059.	3.3	32
20	Global Analysis of Protein-Protein Interactions Reveals Multiple CYP2E1-Reductase Complexes. <i>Biochemistry</i> , 2007, 46, 10192-10201.	2.5	31
21	Computationally Assessing the Bioactivation of Drugs by N-Dealkylation. <i>Chemical Research in Toxicology</i> , 2018, 31, 68-80.	3.3	30
22	Advances in the interpretation and prediction of CYP2E1 metabolism from a biochemical perspective. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 1053-1064.	3.3	29
23	Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells. <i>Chemical Research in Toxicology</i> , 2016, 29, 101-108.	3.3	27
24	CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling. <i>Archives of Biochemistry and Biophysics</i> , 2007, 459, 59-69.	3.0	24
25	Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. <i>Drug Metabolism Reviews</i> , 2010, 42, 55-61.	3.6	24
26	CYP2E1 hydroxylation of aniline involves negative cooperativity. <i>Biochemical Pharmacology</i> , 2014, 87, 523-533.	4.4	23
27	Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 857-874.	3.3	22
28	4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10497-10511.	6.4	22
29	Beta sheet-alpha helix C loop of cytochrome P450 reductase serves as a docking site for redox partners. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2010, 1804, 1285-1293.	2.3	21
30	The Role of ERp44 in Maturation of Serotonin Transporter Protein. <i>Journal of Biological Chemistry</i> , 2012, 287, 17801-17811.	3.4	21
31	Toxicological implications of mitochondrial localization of CYP2E1. <i>Toxicology Research</i> , 2017, 6, 273-289.	2.1	21
32	CYP2E1 Metabolism of Styrene Involves Allostery. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1976-1983.	3.3	19
33	Subcellular localization of rat CYP2E1 impacts metabolic efficiency toward common substrates. <i>Toxicology</i> , 2015, 338, 47-58.	4.2	18
34	1,3-Butadiene-induced mitochondrial dysfunction is correlated with mitochondrial CYP2E1 activity in Collaborative Cross mice. <i>Toxicology</i> , 2017, 378, 114-124.	4.2	18
35	Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches. <i>Biochemical Pharmacology</i> , 2018, 156, 10-21.	4.4	17
36	The First Aspartic Acid of the DQxD Motif for Human UDP-Glucuronosyltransferase 1A10 Interacts with UDP-Glucuronic Acid during Catalysis. <i>Drug Metabolism and Disposition</i> , 2008, 36, 517-522.	3.3	16

#	ARTICLE	IF	CITATIONS
37	Contribution of Three CYP3A Isoforms to Metabolism of R- and S-Warfarin. <i>Drug Metabolism Letters</i> , 2010, 4, 213-219.	0.8	16
38	Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam. <i>Toxicology</i> , 2020, 440, 152478.	4.2	16
39	Thermal inactivation of the reductase domain of cytochrome P450 BM3. <i>Archives of Biochemistry and Biophysics</i> , 2005, 439, 165-174.	3.0	15
40	Structure of pyrazole derivatives impact their affinity, stoichiometry, and cooperative interactions for CYP2E1 complexes. <i>Archives of Biochemistry and Biophysics</i> , 2013, 537, 12-20.	3.0	14
41	Structural basis for cooperative binding of azoles to CYP2E1 as interpreted through guided molecular dynamics simulations. <i>Journal of Molecular Graphics and Modelling</i> , 2015, 56, 43-52.	2.4	14
42	Identification of Hydroxywarfarin Binding Site in Human UDP Glucuronosyltransferase 1A10: Phenylalanine90 Is Crucial for the Glucuronidation of 6- and 7-Hydroxywarfarin but Not 8-Hydroxywarfarin. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2211-2218.	3.3	13
43	Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation. <i>Biochemical Pharmacology</i> , 2019, 170, 113661.	4.4	13
44	Cooperativity in CYP2E1 metabolism of acetaminophen and styrene mixtures. <i>Biochemical Pharmacology</i> , 2015, 97, 341-349.	4.4	12
45	Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1000-1007.	3.3	12
46	CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches. <i>Chemical Research in Toxicology</i> , 2019, 32, 1151-1164.	3.3	12
47	Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam. <i>Toxicology Letters</i> , 2021, 338, 10-20.	0.8	12
48	Cooperative effects for CYP2E1 differ between styrene and its metabolites. <i>Xenobiotica</i> , 2013, 43, 755-764.	1.1	10
49	Biotransformation and bioactivation reactions – 2017 literature highlights. <i>Drug Metabolism Reviews</i> , 2018, 50, 221-255.	3.6	9
50	Predicting CYP2C19 catalytic parameters for enantioselective oxidations using artificial neural networks and a chirality code. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 3749-3759.	3.0	8
51	Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites. <i>Archives of Biochemistry and Biophysics</i> , 2014, 564, 244-253.	3.0	8
52	Inhibitory potency of 4-carbon alkanes and alkenes toward CYP2E1 activity. <i>Toxicology</i> , 2014, 318, 51-58.	4.2	7
53	Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics. <i>Drug Metabolism and Disposition</i> , 2021, 49, 133-141.	3.3	7
54	A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes. <i>Chemical Research in Toxicology</i> , 2019, 32, 1707-1721.	3.3	6

#	ARTICLE	IF	CITATIONS
55	Biotransformation and bioactivation reactions â€“ 2018 literature highlights. Drug Metabolism Reviews, 2019, 51, 121-161.	3.6	6
56	Novel advances in biotransformation and bioactivation researchâ€”2019 year in review. Drug Metabolism Reviews, 2020, 52, 333-365.	3.6	5
57	Impacts of diphenylamine NSAID halogenation on bioactivation risks. Toxicology, 2021, 458, 152832.	4.2	5
58	CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs. Biochemical Pharmacology, 2021, 194, 114824.	4.4	5
59	Differences in butadiene adduct formation between rats and mice not due to selective inhibition of CYP2E1 by butadiene metabolites. Toxicology Letters, 2013, 223, 221-227.	0.8	4
60	Novel isomeric metabolite profiles correlate with warfarin metabolism phenotype during maintenance dosing in a pilot study of 29 patients. Blood Coagulation and Fibrinolysis, 2018, 29, 602-612.	1.0	4
61	Regioselectivity significantly impacts microsomal glucuronidation efficiency of R/S-6, 7-, and 8-hydroxywarfarin. Xenobiotica, 2019, 49, 397-403.	1.1	4
62	Novel advances in biotransformation and bioactivation research â€“ 2020 year in review. Drug Metabolism Reviews, 2021, 53, 384-433.	3.6	4
63	Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors. Metabolites, 2021, 11, 390.	2.9	3
64	Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. Molecules, 2020, 25, 4820.	3.8	2
65	The glucuronidation of native and oxidized estrogens can be effectively inhibited by compounds structurally related to UDPâ€“glucuronic acid in human recombinant UGT1A10. FASEB Journal, 2009, 23, 750.2.	0.5	1
66	Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin. Frontiers in Pharmacology, 2021, 12, 805133.	3.5	1
67	Erratum to â€œNovel multi-mode ultra performance liquid chromatographyâ€“tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasmaâ€•[J. Chromatogr. B 879 (2011) 1056â€“1062]. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 919-920, 61.	2.3	0
68	CYP2E1 substrate inhibition. MECHANISTIC INTERPRETATION THROUGH AN EFFECTOR SITE FOR MONOCYCLIC COMPOUNDS.. Journal of Biological Chemistry, 2013, 288, 32640.	3.4	0
69	P151 - Bioactivation of halogenated aromatic drugs into quinone metabolites as precursors to drug-induced hepatotoxicity. Drug Metabolism and Pharmacokinetics, 2020, 35, S68.	2.2	0
70	Formation of Multiple CYP2E1 Complexes Affects Activity. FASEB Journal, 2006, 20, A460.	0.5	0
71	Comparative characterization of UDPâ€“glucuronic acid (UDPâ€“GlcUA) bindingâ€“site directed inhibitors with human UGT2B7 and 1A10.. FASEB Journal, 2009, 23, 750.4.	0.5	0
72	Characterization of mutation in the 395 DQxD 398 motif of the glucuronic acid binding site in human UGT1A6: Comparison to UGT1A10. FASEB Journal, 2009, 23, 750.5.	0.5	0